A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834

Last updated date
Study Location
Charleston Pediatrics, PA
Charleston, South Carolina, 29403, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Meningococcal Vaccine
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
10-25 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subject aged >=10 and <26 years at the time of enrollment.

- Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

- Negative urine pregnancy test for all female subjects.

- Subjects who have not received, or who have received no more than 1 prior dose within the past 4 years, of a vaccine containing 1 or more ACWY serogroup

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous vaccination with any meningococcal serogroup B or purely polysaccaride
(nonconjugate) meningococcal vaccine.


- Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving
allergen immunotherapy with a licensed product and are not on stable maintenance
doses.


- A known or suspected defect of the immune system that would prevent an immune response
to the vaccine, such as subjects with congenital or acquired defects in B cell
function, those receiving chronic systemic (oral, intravenous, or intramuscular)
corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the
United States with terminal complement deficiency are excluded from participation in
this study.


- Significant neurological disorder or history of seizure (excluding simple febrile
seizure).


- Current chronic use of systemic antibiotics.


- Received any investigational vaccines, drugs, or devices within 28 days before
administration of the first study vaccination.


- Any neuroinflammatory or autoimmune condition, including, but not limited to,
transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Meningococcal VaccineStudy to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
NCT04819113
  1. Santiago de Compostela, A Coruna
ALL GENDERS
76 Days+
years
MULTIPLE SITES
Meningococcal VaccineA Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
NCT04645966
  1. Santiago de Compostela, A Coruna
  2. Badalona, Barcelona
  3. Sant Cugat del Valles, Barcelona
  4. Burgos, Castilla Y LEON
  5. Móstoles, Madrid
  6. L'Eliana, Valencia
  7. Paiporta, Valencia
  8. Almeria,
  9. Madrid,
  10. Madrid,
  11. Madrid,
  12. Madrid,
  13. Malaga,
  14. Sevilla,
  15. Sevilla,
  16. Valencia,
  17. Valencia,
  18. Valencia,
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Meningococcal VaccineA Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
NCT04440176
  1. North Charleston, South Carolina
  2. Mobile, Alabama
  3. San Diego, California
  4. Orlando, Florida
  5. Atlanta, Georgia
  6. Norfolk, Nebraska
  7. Cincinnati, Ohio
  8. Cincinnati, Ohio
  9. Dayton, Ohio
  10. Fort Worth, Texas
  11. Fort Worth, Texas
  12. San Antonio, Texas
  13. Kaysville, Utah
  14. Murray, Utah
  15. Orem, Utah
  16. Roy, Utah
  17. Salt Lake City, Utah
  18. Salt Lake City, Utah
  19. South Jordan, Utah
  20. Syracuse, Utah
  21. Charlottesville, Virginia
ALL GENDERS
11 Years+
years
MULTIPLE SITES
Meningococcal VaccineMenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
NCT04440163
  1. Cooper City, Florida
  2. Miami Lakes, Florida
  3. Oviedo, Florida
  4. Hradec Kralove,
  5. Birmingham, Alabama
  6. Birmingham, Alabama
  7. Tempe, Arizona
  8. Banning, California
  9. Madera, California
  10. Paramount, California
  11. Paramount, California
  12. Colorado Springs, Colorado
  13. Coral Gables, Florida
  14. Jupiter, Florida
  15. Lake Worth, Florida
  16. Miami Lakes, Florida
  17. Miami, Florida
  18. Miami, Florida
  19. Miami, Florida
  20. Ormond Beach, Florida
  21. Tampa, Florida
  22. Adairsville, Georgia
  23. Chamblee, Georgia
  24. Meridian, Idaho
  25. Nampa, Idaho
  26. Mishawaka, Indiana
  27. South Bend, Indiana
  28. Ankeny, Iowa
  29. West Des Moines, Iowa
  30. El Dorado, Kansas
  31. Newton, Kansas
  32. Lexington, Kentucky
  33. Baton Rouge, Louisiana
  34. Haughton, Louisiana
  35. Saint Louis, Missouri
  36. Elkhorn, Nebraska
  37. Omaha, Nebraska
  38. Binghamton, New York
  39. Salisbury, North Carolina
  40. Wilmington, North Carolina
  41. Winston-Salem, North Carolina
  42. Cleveland, Ohio
  43. Cleveland, Ohio
  44. Dayton, Ohio
  45. Fairfield, Ohio
  46. Norman, Oklahoma
  47. Yukon, Oklahoma
  48. Erie, Pennsylvania
  49. Philadelphia, Pennsylvania
  50. Charleston, South Carolina
  51. Greenville, South Carolina
  52. Bristol, Tennessee
  53. Bristol, Tennessee
  54. Chattanooga, Tennessee
  55. Kingsport, Tennessee
  56. Carrollton, Texas
  57. Plano, Texas
  58. Plano, Texas
  59. San Antonio, Texas
  60. Holladay, Utah
  61. Provo, Utah
  62. Salt Lake City, Utah
  63. Salt Lake City, Utah
  64. South Jordan, Utah
  65. Ceske Budejovice,
  66. Jindrichuv Hradec,
  67. Pardubice,
  68. Praha 6,
  69. Pribram,
  70. Aarhus N,
  71. Balatonfüred,
  72. Debrecen,
  73. Gyula,
  74. Miskolc,
  75. Székesfehérvár,
  76. Debica,
  77. Krakow,
  78. Krakow,
  79. Leczna,
  80. Siemianowice Slaskie,
  81. Trzebnica,
ALL GENDERS
10 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
Official Title  ICMJE A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A BIVALENT RLP2086-CONTAINING PENTAVALENT VACCINE (MENABCWY) IN HEALTHY SUBJECTS>=10 TO <26 YEARS OF AGE
Brief Summary This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studyng safety and immunogenicity of a meningococcal pentavalent vaccine.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Meningococcal Vaccine
Intervention  ICMJE
  • Biological: MenABCWY
    N meningitidis group A, B, C, W, and Y vaccine
  • Biological: Saline
    Placebo
  • Biological: rLP2086
    Bivalent recombinant lipoprotein 2086 vaccine
  • Biological: MenACWY-CRM
    meningococcal group A, C, W-135, and Y conjugate vaccine
Study Arms  ICMJE
  • Experimental: Group 1 (ACWY Naive subjects, MenABCWY/Saline)
    ACWY Naive subjects, MenABCWY/Saline
    Interventions:
    • Biological: MenABCWY
    • Biological: Saline
  • Experimental: Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)
    ACWY Naive subjects, rLP2086/MenACWY-CRM
    Interventions:
    • Biological: rLP2086
    • Biological: MenACWY-CRM
  • Experimental: Group 3 (ACWY Experienced subjects, MenABCWY/Saline)
    ACWY Experienced subjects, MenABCWY/Saline
    Interventions:
    • Biological: MenABCWY
    • Biological: Saline
  • Experimental: Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)
    ACWY Experienced subjects, rLP2086/MenACWY-CRM
    Interventions:
    • Biological: rLP2086
    • Biological: MenACWY-CRM
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 26, 2017)
1590
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 26, 2022
Estimated Primary Completion Date December 26, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female subject aged >=10 and <26 years at the time of enrollment.
  • Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
  • Negative urine pregnancy test for all female subjects.
  • Subjects who have not received, or who have received no more than 1 prior dose within the past 4 years, of a vaccine containing 1 or more ACWY serogroup

Exclusion Criteria:

  • Previous vaccination with any meningococcal serogroup B or purely polysaccaride (nonconjugate) meningococcal vaccine.
  • Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  • A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.
  • Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  • Current chronic use of systemic antibiotics.
  • Received any investigational vaccines, drugs, or devices within 28 days before administration of the first study vaccination.
  • Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 10 Years to 25 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Czechia,   Finland,   Poland,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03135834
Other Study ID Numbers  ICMJE B1971057
2016-004421-17 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP